Gold prices slip after rallying on Powell rate cut talk
Castle Biosciences Inc . (NASDAQ:CSTL), a medical laboratory services provider currently trading near its 52-week low of $15.70, announced amendments to its corporate charter following the annual stockholders meeting held on May 22, 2025. According to InvestingPro data, the company’s stock has experienced significant pressure, declining about 47% over the past six months, though analysis suggests the stock may be undervalued at current levels. The company, headquartered in Friendswood, Texas, filed an 8-K report with the Securities and Exchange Commission detailing the outcomes of the meeting, including the addition of a new article to its Amended and Restated Certificate of Incorporation (A&R Charter).
The newly added Article IX to the A&R Charter aims to limit the liability of the company’s officers to the extent permitted by the General Corporation Law of the State of Delaware (DGCL). This amendment was approved at the annual meeting and became effective upon filing with the Secretary of State of Delaware.
During the annual meeting, stockholders also voted on several key proposals. The election of directors saw the appointment of three Class III Directors, each to serve until the company’s 2028 annual meeting. The directors elected were Kimberlee S. Caple, G. Bradley Cole, and Derek J. Maetzold, with the majority of votes cast in favor of their appointments.
Additionally, the stockholders ratified the selection of KPMG LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.
The compensation of the company’s named executive officers was approved on an advisory basis, with a majority of votes in favor. This proposal was part of the company’s efforts to maintain transparency and align the interests of its executives with those of its shareholders.
Finally, the A&R Charter amendment to limit officer liability was approved, with stockholders casting a significant majority in favor of the proposal.
Castle Biosciences specializes in providing diagnostic and prognostic testing services for dermatologic cancers. The company’s SEC filing and the outcomes of the annual meeting reflect its ongoing commitment to corporate governance and shareholder rights. The full text of the A&R Charter, as amended, is filed with the SEC and incorporated by reference in the 8-K report.
In other recent news, Castle Biosciences reported a 21% year-over-year revenue increase for the first quarter of 2025, reaching $88 million. Despite this revenue growth, the company missed earnings per share expectations, reporting an EPS of -$0.20 against a forecasted -$0.06. The company has raised its full-year revenue guidance to a range of $287-$297 million, indicating confidence in continued growth. Castle Biosciences also announced the acquisition of Previse, a firm specializing in gastrointestinal diagnostics, to enhance its TissueCypher platform. This acquisition is expected to bolster offerings in esophageal cancer care, although no immediate revenue impact is anticipated. Scotiabank (TSX:BNS) and BTIG adjusted their price targets for Castle Biosciences to $40 and $32, respectively, maintaining positive ratings. KeyBanc Capital Markets reiterated an Overweight rating with a $36 price target, citing strong performance in the TissueCypher test volumes. Additionally, Castle Biosciences confirmed the efficacy of its DecisionDx-UM test for uveal melanoma through independent validation, reinforcing its commitment to improving health outcomes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.